Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo for relapsed AML stalls as trial ends early

NCT ID NCT05799079

Terminated Disease control Sponsor: Sanjay Mohan Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of three oral drugs—decitabine, cedazuridine, and venetoclax—in adults whose acute myeloid leukemia (AML) came back after a donor stem cell transplant. The goal was to see if the drugs could kill cancer cells and achieve a complete remission. However, the study was terminated early after enrolling only one person, so no meaningful conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
decitabine, cedazuridine, and venetoclax
What this could lead to
If it worked, this combination could offer a new treatment option for AML that returns after a stem cell transplant.
What could go wrong
The trial was terminated early with only 1 participant, so we have very little data. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.